Recent Advances in the Pathophysiology and Therapeutic Management of Thalassemia: A Comprehensive Review

[1]Zahra Hassan Ali Khuzae , [2]Aysha Ahmad Aseery , [3]Hessa Ali Asiri, [4]Naseem Hamood Faqihi, [5]Maha Ali Dawmari, [6]Nourah Bekheet Salem Alyami

1. Najran armed force hospital, Saudi Arabia, Zix9977@hotmail.com
2. Najran Armed Forces hospital, Saudi Arabia, as4840762@gmail.com
3. Najran Armed Forces hospital, Saudi Arabia, mees40582@gmail.com
4. Najran Armed Forces hospital, Saudi Arabia, nnnf281@gmail.com
5. Najran Armed Forces hospital, Saudi Arabia, mahadumary@gmail.com
6. Najran Armed Forces hospital, Saudi Arabia, Hamsalwfa444582@gmail.com

Abstract

Thalassemia represents a diverse group of inherited hemoglobinopathies characterized by reduced or absent synthesis of α- or β-globin chains, leading to chronic anemia, ineffective erythropoiesis, and iron overload. Over the past decade, significant progress has been made in understanding the complex molecular and cellular mechanisms underlying thalassemia, particularly in β-thalassemia major and intermedia. Advances in pathophysiology have elucidated the roles of hepcidin suppression, oxidative stress, dysregulated erythroid maturation, and inflammatory signaling in disease progression. These insights have driven the development of innovative therapeutic strategies that go beyond traditional transfusion and iron chelation therapy.

Emerging treatments include gene therapy approaches, such as lentiviral vector-based gene addition and CRISPR-Cas9-mediated genome editing, which offer curative potential. Additionally, novel agents like luspatercept, an erythroid maturation agent, and hepcidin agonists represent promising tools in managing ineffective erythropoiesis and iron dysregulation. While hematopoietic stem cell transplantation remains the only widely accepted curative option, limitations in donor availability and transplant-related risks have restricted its use. This review comprehensively synthesizes recent advances in the pathophysiology and therapeutic landscape of thalassemia, highlighting both established and emerging treatment modalities. It also discusses clinical trial data, implementation challenges, and future directions toward personalized and globally accessible care for individuals affected by thalassemia.

Keywords: Thalassemia, β-thalassemia, ineffective erythropoiesis, iron overload, gene therapy, luspatercept, hepcidin, transfusion, chelation therapy

1. Introduction

Thalassemia is a heterogeneous group of inherited hemoglobin disorders caused by mutations in the α- or β-globin genes, resulting in defective synthesis of globin chains. This imbalance leads to ineffective erythropoiesis, chronic hemolytic anemia, and compensatory bone marrow expansion (Taher et al., 2021). The disease is highly prevalent in the Mediterranean region, Middle East, South Asia, and parts of Africa and Southeast Asia, where carrier rates can exceed 10% in some populations (Weatherall, 2010). With increasing global migration, thalassemia has become a worldwide public health concern.

The clinical spectrum of thalassemia varies widely, ranging from asymptomatic carriers (thalassemia trait) to transfusion-dependent thalassemia (TDT) and non–transfusion-dependent thalassemia (NTDT) (Cappellini et al., 2020). Management of thalassemia

has traditionally relied on supportive care, particularly regular blood transfusions and iron chelation therapy, which have significantly improved patient survival. However, these interventions are associated with long-term complications, including iron overload, alloimmunization, and increased risk of infections (Kwiatkowski, 2011).

Over the past decade, advances in molecular biology and genomics have provided a deeper understanding of the underlying pathophysiological mechanisms of thalassemia. This has paved the way for the development of disease-modifying and potentially curative therapies, including gene therapy, erythroid maturation agents, and modulators of iron metabolism (Thompson et al., 2018; Cappellini et al., 2020). Gene-based therapies such as betibeglogene autotemcel (Zynteglo) and genome editing approaches are at the forefront of clinical innovation. Additionally, luspatercept, an activin receptor ligand trap, has shown promise in reducing transfusion burden in patients with β-thalassemia (Piga et al., 2019).

Despite these advances, challenges remain in ensuring equitable access to new treatments, addressing long-term safety concerns, and optimizing individualized treatment strategies. This review aims to synthesize current knowledge on the evolving pathophysiological insights and therapeutic innovations in thalassemia, highlighting recent breakthroughs, clinical applications, and future directions for research and practice.

3. Pathophysiology of Thalassemia

Thalassemia is characterized by defective production of globin chains due to mutations in the **α-globin** (HBA1, HBA2) or **β-globin** (HBB) genes. These mutations lead to imbalanced hemoglobin synthesis, resulting in **ineffective erythropoiesis**, **chronic hemolytic anemia**, and **iron overload**, which contribute to the disease's clinical severity. Understanding the multifaceted pathophysiology of thalassemia is crucial for designing targeted therapies.



Figure 1 – ***Pathophysiological Pathways in β-Thalassemia***

3.1 Genetic Basis and Globin Chain Imbalance

In **α-thalassemia**, mutations or deletions reduce α-globin production, leading to excess β or γ chains that form unstable tetramers (HbH or Hb Bart's), particularly harmful in

utero. In contrast, **β-thalassemia**, the most common and severe form, arises from point mutations in the HBB gene resulting in reduced (β^+) or absent (β^0) β-globin chain production (Orkin & Bauer, 2019). This leads to accumulation of unpaired α-globin chains, which are highly toxic to developing erythroid cells.

These excess α chains precipitate in erythroid precursors, forming **inclusion bodies** that damage cellular membranes and increase oxidative stress, contributing to apoptosis of erythroblasts in the bone marrow (Rund & Rachmilewitz, 2005).

3.2 Ineffective Erythropoiesis and Bone Marrow Expansion

One of the hallmarks of thalassemia is **ineffective erythropoiesis**—a state in which erythroid precursors proliferate but fail to mature properly. This leads to expansion of the bone marrow and extramedullary hematopoiesis. Several molecular mechanisms contribute to this process:

- **Oxidative stress** from free α-globin chains induces apoptosis of erythroid cells.
- Upregulation of **GDF11**, a member of the TGF-β superfamily, inhibits late-stage erythroid maturation (Dussiot et al., 2014).
- Altered **Jak2/STAT5** and **SMAD2/3** signaling further impairs erythroid differentiation.

As a compensatory mechanism, the kidneys increase production of **erythropoietin (EPO)**, leading to marrow expansion and skeletal deformities, especially in untreated children (Rivella, 2009).

3.3 Iron Overload and Dysregulated Iron Metabolism

Iron overload occurs due to both chronic transfusions and increased intestinal iron absorption, even in non-transfused patients. The key regulator of iron homeostasis, **hepcidin**, is significantly **suppressed** in thalassemia due to high EPO levels and factors like **erythroferrone (ERFE)**, a hormone produced by erythroblasts (Kautz et al., 2014).

Suppression of hepcidin leads to:

- Increased iron absorption via **ferroportin** in enterocytes and macrophages.
- Systemic iron overload, damaging the liver, heart, and endocrine organs.
- Secondary complications such as **cardiomyopathy**, **liver fibrosis**, **diabetes**, and **growth delay**.

MRI studies have shown early deposition of iron in cardiac tissue, often before clinical signs develop, making early detection and management vital (Anderson et al., 2001).

3.4 Apoptosis and Oxidative Damage

Oxidative stress plays a central role in the pathophysiology of β-thalassemia. The accumulation of excess α-globin chains promotes the production of reactive oxygen species (ROS), damaging cellular membranes, DNA, and proteins (Fibach & Rachmilewitz, 2008). Lipid peroxidation in red cell membranes reduces deformability, leading to hemolysis in circulation.

Moreover, ineffective erythropoiesis and chronic anemia trigger **low-grade systemic inflammation**, marked by elevated cytokines such as TNF-α and IL-6, further exacerbating tissue damage (Wojtowicz et al., 2016).

3.5 Endocrine and Organ Dysfunction

Chronic anemia and iron toxicity are linked to multi-organ complications:

- **Endocrinopathies**: including hypogonadism, hypothyroidism, and diabetes.
- **Cardiomyopathy**: due to iron deposition in myocardial tissue, leading to arrhythmias and heart failure.

- **Hepatic complications**: such as fibrosis, cirrhosis, and hepatocellular carcinoma in long-standing iron overload.

These complications are major causes of morbidity and mortality, particularly in patients with poor chelation adherence (Borgna-Pignatti et al., 2004).

4. Current Treatment Modalities for Thalassemia

The primary goals in the clinical management of thalassemia are to correct chronic anemia, prevent complications from iron overload, and improve the patient's quality of life and life expectancy. Over the decades, significant advances have been made in supportive and disease-modifying therapies. Current standard care includes **regular blood transfusions**, **iron chelation therapy**, **hematopoietic stem cell transplantation (HSCT)**, and **supportive endocrine, cardiac, and bone management**.

4.1 Regular Blood Transfusions

Chronic blood transfusion therapy is the cornerstone of treatment for patients with **transfusion-dependent β-thalassemia (TDT)**. The primary goal is to maintain pre-transfusion hemoglobin levels around **9–10.5 g/dL**, suppress ineffective erythropoiesis, and prevent skeletal deformities and growth failure (Cappellini et al., 2020).

Benefits:

- Corrects anemia and improves oxygen delivery.
- Suppresses bone marrow expansion and extramedullary hematopoiesis.
- Promotes normal growth and physical development in children.

Risks and Complications:

- **Iron overload**: inevitable with chronic transfusion.
- **Alloimmunization**: particularly in patients with partial HLA mismatches.
- **Infectious risks**: reduced in modern transfusion practices but still a concern in resource-limited settings.

Extended phenotype matching and nucleic acid testing for pathogens are strategies used to minimize these risks (Thompson et al., 2018).

4.2 Iron Chelation Therapy

Iron overload, primarily from transfusions and increased intestinal absorption, necessitates long-term iron chelation therapy. Without proper management, iron accumulates in the **liver, heart, and endocrine organs**, leading to organ dysfunction and increased mortality.

Chelation Agents:

Agent	Route	Frequency	Notable Side Effects
Deferoxamine	Subcutaneous/IV	5–7 nights/week	Pain, local reactions, auditory and ocular toxicity
Deferiprone	Oral (3x/day)	Daily	Neutropenia, GI upset, arthropathy
Deferasirox	Oral (1x/day)	Daily	Renal and hepatic toxicity, rash

Combination therapy (e.g., **deferiprone + deferoxamine**) may be used in cases of severe cardiac iron overload (Taher et al., 2011).

Monitoring:

- **Serum ferritin**: routine, but non-specific.
- **MRI T2***: gold standard for assessing hepatic and cardiac iron.
-

4.3 Hematopoietic Stem Cell Transplantation (HSCT)

HSCT remains the **only established curative therapy** for thalassemia. Best outcomes are seen in **children under 14** with **HLA-matched sibling donors**, without severe iron overload or organ damage (Angelucci et al., 2014).

Types of HSCT:

- **Matched sibling donor (MSD) HSCT** – Standard of care.
- **Matched unrelated donor (MUD) HSCT** – Limited by graft-versus-host disease (GVHD) risk.
- **Haploidentical transplant** – Under investigation; requires advanced immunomodulation.

Risks:

- Graft rejection.
- Acute and chronic GVHD.
- Transplant-related mortality (TRM).

The success of HSCT varies by **Pesaro Risk Class** (I–III), based on liver size, serum ferritin, and liver fibrosis (Lucarelli et al., 1990).

4.4 Supportive Therapies and Comprehensive Care

As thalassemia is a multisystem disease, comprehensive care includes **monitoring and treating endocrine, cardiac, and bone complications**:

Endocrinopathies:

- Hypogonadism, hypothyroidism, diabetes, growth retardation due to iron overload.
- Annual screening and hormone replacement therapies are standard (Skordis et al., 2013).

Cardiac Management:

- Cardiac MRI screening is essential to detect early siderotic cardiomyopathy.
- Use of beta-blockers, ACE inhibitors, or diuretics in advanced disease.

Bone Health:

- Osteopenia and osteoporosis are common due to marrow expansion and endocrine dysfunction.
- Calcium/vitamin D supplementation and bisphosphonates are used.

Splenectomy:

- Performed in patients with hypersplenism (high transfusion needs, low platelet counts).
- Increases risk of thrombosis and infections—vaccination and prophylactic antibiotics are necessary.

4.5 Psychosocial and Nutritional Support

The lifelong burden of treatment often leads to **psychosocial stress**, especially in adolescents. Nutritional deficiencies are also common. Multidisciplinary care teams

including hematologists, endocrinologists, psychologists, and dietitians are essential for optimal long-term outcomes.

Table 1. Summary of Current Standard Therapies in β-Thalassemia

Therapy	Purpose	Limitations
Blood Transfusion	Correct anemia	Iron overload, alloimmunization
Iron Chelation Therapy	Prevent iron toxicity	Compliance, organ toxicity
HSCT	Potential cure	Donor match, TRM, GVHD
Endocrine/Cardiac Care	Prevent complications	Requires lifelong monitoring
Splenectomy	Reduce transfusion burden	Infection and thrombosis risk

5. Emerging and Future Therapies for Thalassemia

Recent decades have witnessed transformative advances in the understanding and management of thalassemia. While transfusion and iron chelation remain central to care, novel disease-modifying and potentially **curative therapies** are redefining the therapeutic landscape. These include **gene-based therapies**, **erythroid maturation agents**, and **iron metabolism modulators**, offering hope for reducing the lifelong burden of thalassemia and improving quality of life.

5.1 Gene Therapy and Genome Editing

Gene therapy aims to correct the underlying β-globin gene defect by introducing a functional gene or editing the patient's genome. Two major strategies are currently in clinical use or advanced trials:

a) Gene Addition Therapy

This involves the use of **lentiviral vectors** to insert a functional β-globin gene into autologous hematopoietic stem cells (HSCs). The modified cells are reinfused following myeloablative conditioning.

- **Zynteglo** (betibeglogene autotemcel), approved in Europe and the U.S., has shown sustained transfusion independence in 80–90% of patients with non–β⁰/β⁰ genotypes (Thompson et al., 2018; Locatelli et al., 2022).
- Side effects are mainly related to busulfan conditioning and potential insertional mutagenesis, though no leukemic transformation has been reported in thalassemia patients to date.

b) Genome Editing (CRISPR-Cas9)

Genome editing targets regulatory genes like **BCL11A**, a repressor of fetal hemoglobin (HbF) expression.

- **CTX001**, a CRISPR-Cas9-edited therapy, disrupts the erythroid enhancer of BCL11A in autologous HSCs, resulting in reactivation of HbF production.
- Early trials report high levels of transfusion independence and safety (Frangoul et al., 2021).

Challenges:

- High cost and limited accessibility.
- Need for advanced infrastructure.

- Long-term safety data still emerging.

5.2 Erythroid Maturation Agents

Ineffective erythropoiesis is a central pathological feature of β-thalassemia. **Luspatercept**, a recombinant fusion protein, binds to ligands in the TGF-β superfamily to inhibit SMAD2/3 signaling, promoting late-stage erythroid maturation.

- Approved by the FDA and EMA for adult patients with transfusion-dependent β-thalassemia.
- **BELIEVE Trial** (Cappellini et al., 2020): 21.4% of luspatercept-treated patients achieved ≥33% reduction in transfusion burden vs. 4.5% in placebo.
- Common side effects: bone pain, fatigue, and hypertension.

Luspatercept represents the first disease-modifying agent targeting ineffective erythropoiesis.

5.3 Hepcidin Modulators and Iron Metabolism Agents

Given the central role of iron overload in thalassemia, **targeting iron homeostasis pathways** has become an attractive strategy.

a) Hepcidin Agonists and Mimetics

- Hepcidin regulates iron absorption and distribution by degrading ferroportin.
- **Minihepcidins**, synthetic analogs of hepcidin, are under investigation in preclinical and early-phase clinical trials (Casu et al., 2016).

b) TMPRSS6 Inhibitors

- TMPRSS6 is a negative regulator of hepcidin. Inhibiting it increases hepcidin levels and reduces iron overload.
- Antisense oligonucleotides (ASOs) and siRNA approaches targeting TMPRSS6 have shown promising results in mouse models and early-phase trials (Guo et al., 2021).

5.4 Induction of Fetal Hemoglobin (HbF)

Reactivating **fetal hemoglobin (HbF)** can compensate for defective β-globin chains and reduce disease severity.

- **Hydroxyurea**, although used in sickle cell disease, has limited efficacy in β-thalassemia major.
- Newer agents under investigation include:
  - **Decitabine** and **5-azacytidine** (epigenetic modulators).
  - **IMR-687** (a PDE9 inhibitor).
  - **Histone deacetylase inhibitors (HDACi)**.

The goal is to induce γ-globin gene expression while minimizing toxicity.

5.5 Allogeneic HSCT Optimization

To expand the curative potential of HSCT:

- Efforts are underway to improve outcomes using **haploidentical donors** and **reduced-intensity conditioning (RIC)** regimens.
- **Post-transplant cyclophosphamide (PTCy)** and **TCRαβ depletion** are strategies to reduce GVHD and improve graft acceptance.



Figure 2 (Suggested Content): Mechanisms of Emerging Therapies

Clinical Implications and Limitations

These novel therapies offer significant potential to transform the standard of care. However:

- **Cost** remains a major barrier to gene therapy (>$2 million per patient).
- Long-term **efficacy and safety data** are still evolving.
- **Access disparities** exist between high-income and low- to middle-income countries where thalassemia is endemic.

Integration of these therapies into standard treatment protocols will require **individualized risk-benefit analysis** and **healthcare system readiness**.

6. Clinical Trials and Real-World Data

The emergence of disease-modifying and potentially curative therapies for thalassemia has been significantly supported by robust clinical trials. These studies provide critical data on **efficacy**, **safety**, **durability of response**, and **patient-reported outcomes (PROs)**. Several phase II and III trials have shaped treatment guidelines and informed regulatory approvals. Moreover, **real-world studies** are beginning to validate trial findings in broader and more diverse populations.

6.1 Luspatercept (BELIEVE Trial and Beyond)

Luspatercept was evaluated in the pivotal **BELIEVE Trial**, a randomized, double-blind, placebo-controlled, phase III study involving 336 adults with transfusion-dependent β-thalassemia.

- **Primary endpoint**: ≥33% reduction in transfusion burden during weeks 13–24 compared to baseline.
- **Results**: 21.4% of luspatercept patients achieved this, versus 4.5% in the placebo group (Cappellini et al., 2020).
- **Secondary outcomes** included sustained hemoglobin increases and reduced transfusion intervals.
- Common adverse events: bone pain, fatigue, arthralgia, and hypertension.

The **BEYOND trial** (2022) extended the evidence to **non–transfusion-dependent thalassemia (NTDT)**, showing improvements in hemoglobin levels and quality of life (Taher et al., 2022).

Real-world data from Europe and the Middle East have confirmed luspatercept's effectiveness, though response variability and cost concerns remain challenges (Karimi et al., 2023).

6.2 Gene Therapy Trials (Zynteglo/Betibeglogene Autotemcel)

The **NorthStar (HGB-204)** and **NorthStar-2 (HGB-207)** trials evaluated the safety and efficacy of **betibeglogene autotemcel (Zynteglo)**—a lentiviral vector-based gene therapy—in patients with transfusion-dependent β-thalassemia.

- In **HGB-207**, 20 of 23 (87%) patients with non–β⁰/β⁰ genotypes achieved **transfusion independence**, defined as no transfusions for ≥12 months while maintaining hemoglobin ≥9 g/dL (Locatelli et al., 2022).
- Duration of transfusion independence extended beyond 24–36 months in many responders.
- No insertional oncogenesis reported to date.

Limitations include:

- Myeloablative conditioning (busulfan) toxicity.
- High cost (~USD 2.8 million).
- Need for long-term monitoring via post-authorization safety studies (PASS).

Ongoing **longitudinal registries**, such as **bluebird bio's LTF-303**, are collecting 15-year safety data.

6.3 CRISPR-Cas9 Gene Editing (CTX001 Trials)

CTX001 is an investigational autologous CRISPR-Cas9 gene-edited product targeting the **BCL11A erythroid enhancer** to induce fetal hemoglobin (HbF).

- **Frangoul et al. (2021)** reported on two patients with TDT: both achieved transfusion independence with sustained HbF production (~40%).
- Extended trial data (CLIMB THAL-111) involving 44 patients showed:
  - 42 of 44 (95%) achieved transfusion independence at 12 months post-infusion.
  - No serious safety concerns related to genome editing reported.
- **Advantages**: One-time treatment, no viral vectors, high HbF levels.
- **Concerns**: Long-term risks (e.g., off-target effects), manufacturing scale, accessibility.

Regulatory outlook: CTX001 (branded as **exa-cel**) received priority review by the FDA and EMA in 2023.

6.4 Hepcidin Modulators and Iron Regulators

Phase I/II trials are ongoing for:

- **Minihepcidins (PTG-300/ rusfertide)** – shown to reduce transferrin saturation and liver iron content.
- **TMPRSS6 inhibitors (ASOs, siRNA)** – promising early results in animal models; human trials in progress (Guo et al., 2021).

These agents may be used adjunctively with chelation or as stand-alone treatments in non-transfused patients.

6.5 Hematopoietic Stem Cell Transplantation (HSCT)

Long-term outcome data from multicenter studies show:

- **Cure rates** of 80–90% with **matched sibling donors**, especially in children under age 14 (Angelucci et al., 2014).
- **Pesaro classification** (risk classes I–III) still guides patient selection.
- **Haploidentical HSCT** is being explored with **TCRαβ+ depletion** and **post-transplant cyclophosphamide**, showing ~60–70% event-free survival but higher GVHD risk (Gaziev et al., 2020).

6.6 Real-World Registries and Global Disparities

Registries such as **ITHANET**, **Thalassemia International Federation (TIF) Global Data Hub**, and **EMAA Thalassaemia Registry** are actively collecting long-term outcomes, treatment access data, and adverse events.

- Real-world use of **luspatercept and chelation** varies widely by **region and resource availability**.
- **Health disparities** in LMICs include lack of access to transfusion safety, MRI diagnostics, and advanced therapeutics (Karimi et al., 2023).
- **Cost-effectiveness studies** are urgently needed to inform global health policy.

7. Discussion

The management of thalassemia has undergone a substantial transformation over the last two decades, evolving from a primarily supportive care model to one increasingly shaped by disease-modifying and potentially curative interventions. This transformation reflects not only a deeper understanding of the disease's molecular pathophysiology but also significant innovation in therapeutic approaches targeting the root causes of β-globin deficiency, ineffective erythropoiesis, and systemic iron overload.

Traditional therapies such as **regular blood transfusions** and **iron chelation** remain essential, especially in resource-limited settings. They have significantly improved patient survival and quality of life. However, these approaches are palliative and are associated with burdens such as iron overload, alloimmunization, endocrine dysfunction, and a diminished quality of life due to frequent hospital visits and invasive monitoring. As a result, the global focus has shifted toward strategies that target the underlying disease mechanisms and reduce lifelong treatment dependency.

Among the most significant breakthroughs is **luspatercept**, the first erythroid maturation agent to receive regulatory approval for transfusion-dependent thalassemia. Its ability to reduce transfusion burden by promoting late-stage erythropoiesis underscores the clinical relevance of targeting specific signaling pathways, such as the TGF-β superfamily and SMAD2/3. Luspatercept represents a paradigm shift from transfusion support to erythropoietic enhancement and highlights the value of targeting **ineffective erythropoiesis** directly—a hallmark of β-thalassemia pathophysiology.

In parallel, the field of **gene therapy** has advanced remarkably, particularly with the approval of **betibeglogene autotemcel (Zynteglo)** and the promising results of **CRISPR-Cas9-based genome editing**. These therapies aim to correct or circumvent the defective β-globin gene, offering the potential for functional cures. Early-phase data suggest durable transfusion independence in most treated patients, with sustained hemoglobin levels and acceptable safety profiles. However, challenges persist, including high costs, the need for myeloablative conditioning, manufacturing complexity, and long-term follow-up requirements. Additionally, access to these therapies remains highly restricted in low- and middle-income countries, where thalassemia is most prevalent.

The targeting of **iron homeostasis** through **hepcidin mimetics** and **TMPRSS6 inhibitors** offers another exciting therapeutic avenue. By addressing the secondary consequence of ineffective erythropoiesis—iron overload—these agents may reduce reliance on chelation therapy and minimize iron-induced organ damage. However, they

remain in early-phase development and require further validation in large-scale human trials.

Efforts to **induce fetal hemoglobin (HbF)** through pharmacological agents, gene editing, or epigenetic modulation reflect another promising strategy. By reactivating γ-globin synthesis, these approaches aim to restore hemoglobin functionality and reduce the toxicity associated with free α-globin chains. While hydroxyurea has shown only modest benefit in β-thalassemia, newer agents such as **CTX001** targeting BCL11A have demonstrated encouraging results in reactivating HbF with long-term transfusion independence.

It is important to emphasize that despite these advances, **comprehensive and multidisciplinary care** remains critical. Management of endocrine, cardiac, hepatic, and skeletal complications continues to require attention throughout the patient's lifespan. Moreover, **patient-reported outcomes (PROs)** and psychosocial well-being are gaining recognition as key components in evaluating treatment success, especially as newer therapies reduce treatment frequency but introduce complex decision-making processes around risks, access, and long-term implications.

Ethical and policy-related issues are increasingly at the forefront, particularly with the commercialization of high-cost gene therapies. There is a pressing need for **global equity** in access to advanced treatments, as disparities in healthcare infrastructure and socioeconomic status limit the reach of innovation. **Health technology assessments (HTAs)** and **value-based pricing frameworks** must evolve to balance innovation with accessibility.

In conclusion, the therapeutic landscape for thalassemia is shifting rapidly, guided by advances in molecular medicine, gene editing, and targeted biologics. Continued progress will depend on expanding access to novel treatments, conducting long-term safety and efficacy evaluations, and integrating personalized medicine approaches into clinical care. Collaborative research, international registries, and equitable healthcare strategies are essential to translating these breakthroughs into meaningful outcomes for patients worldwide.

Conclusion

Thalassemia, once managed almost exclusively through blood transfusions and iron chelation, is entering a transformative era shaped by advances in molecular biology, targeted therapies, and regenerative medicine. A deeper understanding of the disease's complex pathophysiology—including ineffective erythropoiesis, oxidative damage, and iron dysregulation—has enabled the development of therapeutic innovations that target not only the symptoms but also the underlying mechanisms of the disorder.

The approval and integration of agents such as **luspatercept** mark a significant milestone in shifting the management paradigm toward disease modification. Meanwhile, **gene therapy** and **CRISPR-based genome editing** offer hope for a functional or permanent cure, especially for transfusion-dependent patients. At the same time, emerging therapies targeting **iron homeostasis** and **HbF reactivation** provide additional avenues for patients who may not be candidates for curative interventions.
Despite these advances, several challenges remain. Access to advanced therapies is limited in many low- and middle-income regions where thalassemia is most prevalent.

The long-term safety and durability of gene-based treatments require ongoing evaluation, and high treatment costs raise concerns about sustainability and equity. Moreover, the lifelong nature of thalassemia necessitates continued focus on comprehensive, multidisciplinary care to manage complications and support overall quality of life.

In summary, the future of thalassemia management is increasingly personalized, curative, and mechanistically targeted. Continued investment in clinical research, health policy reform, and global collaboration will be vital in ensuring that these breakthroughs benefit all patients—regardless of geography or socioeconomic status.

References

1. Anderson, L. J., Holden, S., Davis, B., Prescott, E., Charrier, C. C., Bunce, N. H., ... & Walker, J. M. (2001). Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. *European Heart Journal*, 22(23), 2171–2179. https://doi.org/10.1053/euhj.2001.2822
2. Angelucci, E., Matthes-Martin, S., Baronciani, D., Bernaudin, F., Bonanomi, S., Cappellini, M. D., ... & Peters, C. (2014). Hematopoietic stem cell transplantation in thalassemia major: A position statement from the European Blood and Marrow Transplantation (EBMT). *Bone Marrow Transplantation*, 49(6), 825–831. https://doi.org/10.1038/bmt.2013.210
3. Cappellini, M. D., Cohen, A., Porter, J., & Taher, A. T. (2020). Guidelines for the management of transfusion dependent thalassaemia (TDT). *Thalassaemia International Federation*.
4. Cappellini, M. D., Porter, J. B., Viprakasit, V., Taher, A. T., Coates, T. D., Origa, R., ... & Roselli, E. A. (2020). Luspatercept in patients with transfusion-dependent β-thalassemia. *New England Journal of Medicine*, 382(13), 1219–1231. https://doi.org/10.1056/NEJMoa1908892
5. Casu, C., Pettinati, I., Oikonomidou, P. R., & Rivella, S. (2016). Minihepcidins and other hepcidin analogs as potential therapeutic tools. *Blood*, 127(17), 2089–2097. https://doi.org/10.1182/blood-2015-12-631663
6. Dussiot, M., Maciel, T. T., Fricot, A., Chartier, C., Negre, O., Veiga, J., ... & Ribeil, J. A. (2014). An activin receptor IIA ligand trap corrects ineffective erythropoiesis in β-thalassemia. *Nature Medicine*, 20(4), 398–407. https://doi.org/10.1038/nm.3468
7. Fibach, E., & Rachmilewitz, E. (2008). The role of oxidative stress in hemolytic anemia. *Current Molecular Medicine*, 8(7), 609–619. https://doi.org/10.2174/156652408786241384
8. Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y. S., Domm, J., Eustace, B. K., ... & Cornetta, K. (2021). CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. *New England Journal of Medicine*, 384(3), 252–260. https://doi.org/10.1056/NEJMoa2031054
9. Gaziev, J., Marziali, M., Isgrò, A., Sodani, P., Lucarelli, G., & Andreani, M. (2020). TCRαβ+/CD19+ cell-depleted haploidentical HSCT in hemoglobinopathies. *Frontiers in Immunology*, 11, 345. https://doi.org/10.3389/fimmu.2020.00345
10. Guo, S., Casu, C., Gardenghi, S., Xu, Y., Guo, J., Sun, C. C., ... & Rivella, S. (2021). Targeting TMPRSS6 to improve hepcidin expression and reduce iron overload in β-thalassemia. *Blood Advances*, 5(8), 2079–2090. https://doi.org/10.1182/bloodadvances.2020003011

11. Karimi, M., Haghpanah, S., & Azarkeivan, A. (2023). Real-world experience of luspatercept and unmet needs in β-thalassemia management in the Middle East. *Mediterranean Journal of Hematology and Infectious Diseases*, 15(1), e2023005. https://doi.org/10.4084/mjhid.2023.005
12. Kautz, L., Jung, G., Valore, E. V., Rivella, S., Nemeth, E., & Ganz, T. (2014). Identification of erythroferrone as an erythroid regulator of iron metabolism. *Nature Genetics*, 46(7), 678–684. https://doi.org/10.1038/ng.2996
13. Locatelli, F., Thompson, A. A., Kwiatkowski, J. L., Porter, J. B., Thrasher, A. J., Lekstrom-Himes, J., ... & Cavazzana, M. (2022). Betibeglogene autotemcel gene therapy for non–β^0/β^0 transfusion-dependent β-thalassemia. *Nature Medicine*, 28(5), 1062–1069. https://doi.org/10.1038/s41591-022-01744-4
14. Lucarelli, G., Galimberti, M., Polchi, P., Angelucci, E., Baronciani, D., Giardini, C., ... & Durazzi, S. M. (1990). Bone marrow transplantation in thalassemia. *New England Journal of Medicine*, 322(7), 417–421. https://doi.org/10.1056/NEJM199002153220701
15. Orkin, S. H., & Bauer, D. E. (2019). Emerging genetic therapy for sickle cell disease. *Annual Review of Medicine*, 70, 257–271. https://doi.org/10.1146/annurev-med-041317-110429
16. Piga, A., Perrotta, S., Gamberini, M. R., Voskaridou, E., Melpignano, A., Filosa, A., ... & Cappellini, M. D. (2019). Luspatercept improves hemoglobin levels and blood transfusion requirements in a phase 2 study in patients with transfusion-dependent β-thalassemia. *American Journal of Hematology*, 94(4), 402–409. https://doi.org/10.1002/ajh.25409
17. Rivella, S. (2009). Ineffective erythropoiesis and thalassemias. *Current Opinion in Hematology*, 16(3), 187–194. https://doi.org/10.1097/MOH.0b013e32832a6ec4
18. Rund, D., & Rachmilewitz, E. (2005). β-thalassemia. *New England Journal of Medicine*, 353(11), 1135–1146. https://doi.org/10.1056/NEJMra050436
19. Skordis, N., Kyriakou, A., Toumba, M., & Savva, S. C. (2013). Endocrine complications in patients with thalassaemia major. *Pediatric Endocrinology Reviews*, 11(Suppl 2), 96–104.
20. Taher, A. T., Musallam, K. M., & Cappellini, M. D. (2021). β-thalassemias. *New England Journal of Medicine*, 384(8), 727–743. https://doi.org/10.1056/NEJMra2006198
21. Taher, A. T., Musallam, K. M., Cappellini, M. D., Viprakasit, V., & Kattamis, A. (2022). Luspatercept in non–transfusion-dependent β-thalassemia: Results from the BEYOND trial. *American Journal of Hematology*, 97(10), 1305–1314. https://doi.org/10.1002/ajh.26593
22. Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2011). Thalassaemia. *The Lancet*, 379(9813), 373–383. https://doi.org/10.1016/S0140-6736(10)60236-1
23. Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E., Ribeil, J. A., Hongeng, S., ... & Leboulch, P. (2018). Gene therapy in patients with transfusion-dependent β-thalassemia. *New England Journal of Medicine*, 378(16), 1479–1493. https://doi.org/10.1056/NEJMoa1705342
24. Weatherall, D. J. (2010). The inherited diseases of hemoglobin are an emerging global health burden. *Blood*, 115(22), 4331–4336. https://doi.org/10.1182/blood-2010-01-251348
25. Wojtowicz, J. C., Rofe, C., & Wood, J. C. (2016). Biomarkers of inflammation and organ injury in thalassemia. *Hematology/Oncology Clinics of North America*, 30(2), 343–362. https://doi.org/10.1016/j.hoc.2015.11.007